Talphera, Inc. Appoints Abhinav Jain to Serve as a Class II Director
January 22, 2024 at 05:12 pm EST
Share
Talphera, Inc. announced that Pursuant to terms of the Securities Purchase Agreements with entities affiliated with Nantahala Management, LLC and effective upon the first closing of the Private Placement, which occurred on January 22, 2024, the board of directors of the Company appointed Abhinav Jain to serve as a Class II Director to hold office for the balance of a term expiring at the Company?s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal.
Talphera, Inc., formerly AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The Company is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.